Brokerage firm slashes Orphazyme price target by 77 percent

Following the CHMP’s indication that biotech firm Orphazyme’s drug candidate for rare metabolic disease Niemann-Pick type C will soon be rejected, institutional brokerage firm Danske Markets has decided to further reduce the company share price target.

Photo: Orphazyme/PR

Biotech company Orphazyme has had its share price target lowered to a mere DKK 3 (USD 0.45) from a previous DKK 13 (USD 1.95) by Danish brokerage firm Danske Markets. The firm maintains its recommendation ”sell,” according to financial news service PLX AI.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs